Актуальные вопросы диагностики и психофармакотерапии посттравматического стрессового расстройства
|
Полный текст:
Только для подписчиков
|
Рекомендуемое оформление библиографической ссылки:
Ахапкин Р.В., Вазагаева Т.И. Актуальные вопросы диагностики и психофармакотерапии посттравматического стрессового расстройства // Российский психиатрический журнал. 2025. №1. С. 13-24.
В научном обзоре нарративного типа с целью выявления проблемных вопросов и современных тенденций в диагностике и психофармакотерапии посттравматического стрессового расстройства (ПТСР) проведен анализ научных публикаций российских и зарубежных авторов в библиографических базах PubMed, Google Академия, Science Direct, ResearchGate, Cochrane Library, РИНЦ и КиберЛенинка. Обсуждаются трудности диагностики ПТСР, связанные с многообразием его клинических проявлений, травмирующих факторов и вариантов течения, высокой частотой сопутствующих психических и соматических расстройств. Терапия ПТСР также сопряжена с рядом сложностей в связи с недостаточностью доказанных методов эффективного лекарственного лечения. Актуальными задачами для будущих исследований являются поиск новых лекарственных методов, разработка дифференцированных подходов к терапии и предикторов ее эффективности с целью персонификации лечения пациентов с ПТСР.
Ключевые слова посттравматическое стрессовое расстройство; диагностические критерии; коморбидность; психофармакотерапия; антидепрессанты; антипсихотики; антиконвульсанты; анксиолитики
1. Sabé M, Chen C, El-Hage W, et al. Half a Century of Research on Posttraumatic Stress Disorder: A Scientometric Analysis. Curr Neuropharmacol. 2024;22(4):736–48. DOI: 10.2174/1570159X22666230927143106 2. Herrera-Escobar JP, Seshadri AJ, Stanek E, et al. Mental Health Burden After Injury: It's About More than Just Posttraumatic Stress Disorder. Ann Surg. 2021;274(6):e1162–9. DOI: 10.1097/SLA.0000000000003780 3. Bryant RA. Post-traumatic stress disorder: a state-of-the-art review of evidence and challenges. World Psychiatry. 2019;18(3):259–69. DOI: 10.1002/wps.20656 4. Abramova OV, Zorkina YaA, Ushakova VM, et al. [The mental health consequences of prenatal stress: current understanding of mechanisms]. Rossiiskii psikhiatricheskii zhurnal [Russian Journal of Psychiatry]. 2024;(6):92–106. (In Russ.) 5. Bremner JD, Wittbrodt MT. Stress, the brain, and trauma spectrum disorders. Int Rev Neurobiol. 2020;152:1–22. DOI: 10.1016/bs.irn.2020.01.004 6. Ressler KJ, Berretta S, Bolshakov VY, et al. Post-traumatic stress disorder: clinical and translational neuroscience from cells to circuits. Nat Rev Neurol. 2022;18(5):273–88. DOI: 10.1038/s41582-022-00635-8 7. Psikhicheskie rasstroistva i rasstroistva povedeniya (F00–F99): Klass V MKB-10, adaptirovannyi dlya ispol'zovaniya v Rossiiskoi Federatsii. VB Golland, TB Dmitrieva, BA Kazakovtsev, editors. Moscow: Ministry of Health of the Russian Federation; 1998. p. 215–6. (In Russ.) 8. Utzon-Frank N, Breinegaard N, Bertelsen M, et al. Occurrence of delayed-onset post-traumatic stress disorder: a systematic review and meta-analysis of prospective studies. Scand J Work Environ Health. 2014;40(3):215–29. DOI: 10.5271/sjweh.3420 9. Andrews B, Brewin CR, Philpott R, Stewart L. Delayed-onset posttraumatic stress disorder: a systematic review of the evidence. Am J Psychiatry. 2007;164(9):1319–26. DOI: 10.1176/appi.ajp.2007.06091491 10. Horesh D, Solomon Z, Zerach G, Ein-Dor T. Delayed-onset PTSD among war veterans: the role of life events throughout the life cycle. Soc Psychiatry Psychiatr Epidemiol. 2011;46(9):863–70. DOI: 10.1007/s00127-010-0255-6 11. Bonde JPE, Jensen JH, Smid GE, et al. Time course of symptoms in posttraumatic stress disorder with delayed expression: A systematic review. Acta Psychiatr Scand. 2022;145(2):116–31. DOI: 10.1111/acps.13372 12. Smid GE, van der Velden PG, Lensvelt-Mulders GJ, et al. Stress sensitization following a disaster: a prospective study. Psychol Med. 2012;42(8):1675–86. DOI: 10.1017/S0033291711002765 13. Karavaeva TA, Vasileva AV, Idrisov KA, et al. Posttravaticheskoe stressovoe rasstroystvo. Klinicheskie rekomendatsii. 2023. URL: https://cr.minzdrav.gov.ru/schema/753_1 (accessed on: 17.11.2024). (In Russ.) 14. ICD-11. 6B40. Post-traumatic stress disorder. ICD-WHO-INT. URL: https://icd.who.int/browse/2024-01/mms/en#2070699808 (accessed on: 17.11.2024). 15. Parker AM, Sricharoenchai T, Raparla S, et al. Posttraumatic stress disorder in critical illness survivors: a metaanalysis. Crit Care Med. 2015;43(5):1121–9. DOI: 10.1097/CCM.0000000000000882 16. Lunkenheimer F, Garatva P, Steubl L, Baumeister H. Prevalence and incidence of post-traumatic stress disorder and symptoms in people with chronic somatic diseases: A systematic review and meta-analysis. Front Psychiatry. 2023;14:1107–44. DOI: 10.3389/fpsyt.2023.1107144 17. Yunitri N, Chu H, Kang XL, et al. Global prevalence and associated risk factors of posttraumatic stress disorder during COVID-19 pandemic: A meta-analysis. Int J Nurs Stud. 2022;126:104–36. DOI: 10.1016/j.ijnurstu.2021.104136 18. Vasileva AV. [Pandemic COVID-19 and mental disorders international experience and therapeutic approaches]. Zh Nevrol Psikhiatr Im SS Korsakova. 2020;120(9):121–9. (In Russ.) DOI: 10.17116/jnevro2020120091121 19. ICD-11. 6B41. Complex post-traumatic stress disorder. ICD-WHO-INT. URL: https://icd.who.int/browse/2024-01/mms/en#585833559 (accessed on: 17.11.2024). 20. Letica-Crepulja M, Stevanović A, Protuđer M, et al. Complex PTSD among treatment-seeking veterans with PTSD. Eur J Psychotraumatol. 2020;11(1):1716593. DOI: 10.1080/20008198.2020.1716593 21. Grinsill R, Kolandaisamy M, Kerr K, et al. Prevalence of Complex Post-Traumatic Stress Disorder in Serving Military and Veteran Populations: A Systematic Review. Trauma Violence Abuse. 2024;25(4):3377–87. DOI: 10.1177/15248380241246996 22. Qassem T, Aly-ElGabry D, Alzarouni A, et al. Psychiatric Co-Morbidities in Post-Traumatic Stress Disorder: Detailed Findings from the Adult Psychiatric Morbidity Survey in the English Population. Psychiatr Q. 2021;92(1):321–30. DOI: 10.1007/s11126-020-09797-4 23. Husky MM, Mazure CM, Kovess-Masfety V. Gender differences in psychiatric and medical comorbidity with post-traumatic stress disorder. Compr Psychiatry. 2018;84:75–81. DOI: 10.1016/j.comppsych.2018.04.007 24. Nickerson A, Barnes JB, Creamer M, et al. The temporal relationship between posttraumatic stress disorder and problem alcohol use following traumatic injury. J Abnorm Psychol. 2014;123(4):821–34. DOI: 10.1037/a0037920 25. Hicks EM, Niarchou M, Goleva S, et al. Comorbidity Profiles of Posttraumatic Stress Disorder Across the Medical Phenome. Biol Psychiatry Glob Open Sci. 2024;4(5):100337. DOI: 10.1016/j.bpsgos.2024.100337 26. Veltishchev DYu. [Interrelation of posttraumatic stress disorder and cardiovascular disease]. Sotsial'naya i klinicheskaya psikhiatriya [Social and Clinical Psychiatry]. 2023;33(4):76–80. (In Russ.) DOI: 10.34757/0869-4893.2023.33.4.009 27. Brady KT, McCauley JL, Back SE. The Comorbidity of Post-traumatic Stress Disorder (PTSD) and Substance Use Disorders. In: Textbook of Addiction Treatment. N el-Guebaly, G Carrà, M Galanter, AM Baldacchino, editors. Springer, Cham; 2021. Chapter 93. р. 1327–39. DOI: 10.1007/978-3-030-36391-8_93 28. Hoppen TH, Priebe S, Vetter I, Morina N. Global burden of post-traumatic stress disorder and major depression in countries affected by war between 1989 and 2019: a systematic review and meta-analysis. BMJ Glob Health. 2021;6(7):e006303. DOI: 10.1136/bmjgh-2021-006303 29. Tarabrina NV. Praktikum po psikhologii posttravmaticheskogo stressa. Saint Petersburg: Piter; 2001. 272 р. (In Russ.) 30. Selaman ZM, Chartrand HK, Bolton JM, Sareen J. Which symptoms of post-traumatic stress disorder are associated with suicide attempts? J Anxiety Disord. 2014;28(2):246–51. DOI: 10.1016/j.janxdis.2013.12.005 31. Weber FC, Norra C, Wetter TC. Sleep Disturbances and Suicidality in Posttraumatic Stress Disorder: An Overview of the Literature. Front Psychiatry. 2020;10(11):167. DOI: 10.3389/fpsyt.2020.00167 32. McLaughlin KA, Koenen KC, Friedman MJ, et al. Subthreshold posttraumatic stress disorder in the world health organization world mental health surveys. Biol Psychiatry. 2015;77(4):375–84. DOI: 10.1016/j.biopsych.2014.03.028 33. Panagioti M, Gooding PA, Tarrier N. A meta-analysis of the association between posttraumatic stress disorder and suicidality: the role of comorbid depression. Compr Psychiatry. 2012;53(7):915–30. DOI: 10.1016/j.comppsych.2012.02.009 34. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266–77. DOI: 10.1176/appi.ajp.2011.10111704 35. Bobrov AE. [Some unresolved issues of psychotherapy and organization of stress disorders care]. Sotsial'naya i klinicheskaya psikhiatriya [Social and Clinical Psychiatry]. 2023;33(4):6775. (In Russ.) DOI: 10.34757/0869-4893.2023.33.4.008 36. Mosolov SN. [Therapy and prevention of post-traumatic stress disorder in emergency situations (algorithm of biological therapy)]. Sovremennaja terapija psihicheskih rasstrojstv [Current therapy of mental disorders]. 2022;(3):32–44. (In Russ.) DOI 10.21265/PSYPH.2022.92.41.004 37. Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part II: OCD and PTSD. World J Biol Psychiatry. 2023;24(2):118–34. DOI: 10.1080/15622975.2022.2086296 38. Ressler KJ. Alpha-Adrenergic Receptors in PTSD – Failure or Time for Precision Medicine? N Engl J Med. 2018;378(6):575–6. DOI: 10.1056/NEJMe1716724 39. Davidson J, Pearlstein T, Londborg P, et al. Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. Am J Psychiatry. 2001;158(12):1974–81. DOI: 10.1176/appi.ajp.158.12.1974 40. Rapaport MH, Endicott J, Clary CM. Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. J Clin Psychiatry. 2002;63(1):59–65. DOI: 10.4088/jcp.v63n0112 41. Marshall RD, Lewis-Fernandez R, Blanco C, et al. A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depress Anxiety. 2007;24(2):77–84. DOI: 10.1002/da.20176 42. Tucker P, Zaninelli R, Yehuda R, et al. Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry. 2001;62(11):860–8. DOI: 10.4088/jcp.v62n1105 43. Davidson J, Rothbaum BO, Tucker P, et al. Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. J Clin Psychopharmacol. 2006;26(3):259–67. DOI: 10.1097/01.jcp.0000222514.71390.c1 44. Davidson J, Baldwin D, Stein DJ, et al. Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Arch Gen Psychiatry. 2006;63(10):1158–65. DOI: 10.1001/archpsyc.63.10.1158 45. Martenyi F, Brown EB, Zhang H, et al. Fluoxetine versus placebo in posttraumatic stress disorder. J Clin Psychiatry. 2002;63(3):199–206. DOI: 10.4088/jcp.v63n0305 46. Williams T, Phillips NJ, Stein DJ, Ipser JC. Pharmacotherapy for post-traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2022;3(3):CD002795. DOI: 10.1002/14651858.CD002795.pub3 47. Villarreal G, Cañive JM, Calais LA, et al. Duloxetine in military posttraumatic stress disorder. Psychopharmacol Bull. 2010;43(3):26–34. PMID: 21150844 48. Davis LL, Pilkinton P, Lin C, et al. Efficacy of Vortioxetine Monotherapy for Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Trial. J Clin Psychopharmacol. 2021;41(2):172–9. DOI: 10.1097/JCP.0000000000001363 49. Escalona R, Canive JM, Calais LA, Davidson JR. Fluvoxamine treatment in veterans with combat-related post-traumatic stress disorder. Depress Anxiety. 2002;15(1):29–33. DOI: 10.1002/da.1082 50. Qi W, Gevonden M, Shalev A. Efficacy and Tolerability of High-Dose Escitalopram in Posttraumatic Stress Disorder. J Clin Psychopharmacol. 2017;37(1):89–93. DOI: 10.1097/JCP.0000000000000626 51. Davidson JR, Weisler RH, Butterfield MI, et al. Mirtazapine vs. placebo in posttraumatic stress disorder: a pilot trial. Biol Psychiatry. 2003;53(2):188–91. DOI: 10.1016/s0006-3223(02)01411-7 52. Kim W, Pae CU, Chae JH, et al. The effectiveness of mirtazapine in the treatment of post-traumatic stress disorder: a 24-week continuation therapy. Psychiatry Clin Neurosci. 2005;59(6):743–7. DOI: 10.1111/j.1440-1819.2005.01447.x 53. Davis LL, Pilkinton P, Lin C, et al. A Randomized, Placebo-Controlled Trial of Mirtazapine for the Treatment of Posttraumatic Stress Disorder in Veterans. J Clin Psychiatry. 2020;81(6):20m13267. DOI: 10.4088/JCP.20m13267 54. Lappas AS, Glarou E, Polyzopoulou ZA, et al. Pharmacotherapy for sleep disturbances in post-traumatic stress disorder (PTSD): A network meta-analysis. Sleep Med. 2024;119:467–79. DOI: 10.1016/j.sleep.2024.05.032 55. Warner MD, Dorn MR, Peabody CA. Survey on the usefulness of trazodone in patients with PTSD with insomnia or nightmares. Pharmacopsychiatry. 2001;34(4):128–31. DOI: 10.1055/s-2001-15871 56. Davidson J, Kudler H, Smith R, et al. Treatment of posttraumatic stress disorder with amitriptyline and placebo. Arch Gen Psychiatry. 1990;47(3):259–66. DOI: 10.1001/archpsyc.1990.01810150059010 57. Davidson JR, Kudler HS, Saunders WB, et al. Predicting response to amitriptyline in posttraumatic stress disorder. Am J Psychiatry. 1993;150(7):1024–9. DOI: 10.1176/ajp.150.7.1024 58. Frank JB, Kosten TR, Giller EL Jr, Dan E. A randomized clinical trial of phenelzine and imipramine for posttraumatic stress disorder. Am J Psychiatry. 1988;145(10):1289–91. DOI: 10.1176/ajp.145.10.1289 59. Kosten TR, Frank JB, Dan E, et al. Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. J Nerv Ment Dis. 1991;179(6):366–70. DOI: 10.1097/00005053-199106000-00011 60. Pae CU, Lim HK, Peindl K, et al. The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. Int Clin Psychopharmacol. 2008;23(1):1–8. DOI: 10.1097/YIC.0b013e32825ea324 61. David D, De Faria L, Mellman TA. Adjunctive risperidone treatment and sleep symptoms in combat veterans with chronic PTSD. Depress Anxiety. 2006;23(8):489–91. DOI: 10.1002/da.20187 62. Britnell SR, Jackson AD, Brown JN, Capehart BP. Aripiprazole for Post-traumatic Stress Disorder: A Systematic Review. Clin Neuropharmacol. 2017;40(6):273–8. DOI: 10.1097/WNF.0000000000000251 63. Naylor JC, Kilts JD, Bradford DW, et al. A pilot randomized placebo-controlled trial of adjunctive aripiprazole for chronic PTSD in US military Veterans resistant to antidepressant treatment. Int Clin Psychopharmacol. 2015;30(3):167–74. DOI: 10.1097/YIC.0000000000000061 64. El-Solh AA. Management of nightmares in patients with posttraumatic stress disorder: current perspectives. Nat Sci Sleep. 2018;10:409–20. DOI: 10.2147/NSS.S166089 65. Ramaswamy S, Driscoll D, Smith LM, et al. Failed efficacy of ziprasidone in the treatment of post-traumatic stress disorder. Contemp Clin Trials Commun. 2015;2:1–5. DOI: 10.1016/j.conctc.2015.12.003 66. Hamner MB, Hernandez-Tejada MA, Zuschlag ZD, et al. Ziprasidone Augmentation of SSRI Antidepressants in Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Pilot Study of Augmentation Therapy. J Clin Psychopharmacol. 2019;39(2):153–7. DOI: 10.1097/JCP.0000000000001000 67. Hoskins MD, Bridges J, Sinnerton R, et al. Pharmacological therapy for post-traumatic stress disorder: a systematic review and meta-analysis of monotherapy, augmentation and head-to-head approaches. Eur J Psychotraumatol. 2021;12(1):1802920. DOI: 10.1080/20008198.2020.1802920 68. Villarreal G, Hamner MB, Cañive JM, et al. Efficacy of Quetiapine Monotherapy in Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Trial. Am J Psychiatry. 2016;173(12):1205–12. DOI: 10.1176/appi.ajp.2016.15070967 69. Crapanzano C, Damiani S, Casolaro I, Amendola C. Quetiapine Treatment for Post-traumatic Stress Disorder: A Systematic Review of the Literature. Clin Psychopharmacol Neurosci. 2023;21(1):49–56. DOI: 10.9758/cpn.2023.21.1.49 70. Berlin HA. Antiepileptic drugs for the treatment of post-traumatic stress disorder. Curr Psychiatr Rep. 2007;9(4):291–300. DOI: 10.1007/s11920-007-0035-5 71. Yeh MS, Mari JJ, Costa MC, et al. A double-blind randomized controlled trial to study the efficacy of topiramate in a civilian sample of PTSD. CNS Neurosci Ther. 2011;17(5):305–10. DOI: 10.1111/j.1755-5949.2010.00188.x 72. Varma A, Moore MB, Miller CWT, et al. Topiramate as monotherapy or adjunctive treatment for posttraumatic stress disorder: a meta-analysis. J Trauma Stress. 2018;31(1):125–33. DOI: 10.1002/jts.22251 73. Lindley SE, Carlson EB, Hill K. A randomized, double-blind, placebo-controlled trial of augmentation topiramate for chronic combat-related posttraumatic stress disorder. J Clin Psychopharmacol. 2007;27(6):677–81. DOI: 10.1097/jcp.0b013e31815a43ee 74. Clark RD, Cañive JM, Calais LA, et al. Divalproex in posttraumatic stress disorder: an open label clinical trial. J Trauma Stress. 1999;12(2):395–401. DOI: 10.1023/A:1024797014210 75. Hamner MB, Faldowski RA, Robert S, et al. A preliminary controlled trial of divalproex in posttraumatic stress disorder. Ann Clin Psychiatr. 2009;21(2):89–94. PMID: 19439158 76. Davis LL, Davidson JR, Ward LC, et al. Divalproex in the treatment of posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. J Clin Psychopharmacol. 2008;28(1):84–8. DOI: 10.1097/JCP.0b013e318160f83b 77. De Moraes Costa G, Zanatta FB, Ziegelmannet PK, et al. Pharmacological treatments for adults with post-traumatic stress disorder: a network meta-analysis of comparative efficacy and acceptability. J Psychiatr Res. 2020;130:412–20. DOI: 10.1016/j.jpsychires.2020.07.046 78. Hertzberg MA, Butterfield MI, Feldman ME, et al. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry. 1999;45(9):1226–9. DOI: 10.1016/s0006-3223(99)00011-6 79. Thompson SI, El-Saden SM. Lamotrigine for Treating Anger in Veterans With Posttraumatic Stress Disorder. Clin Neuropharmacol. 2021;44(5):184–5. DOI: 10.1097/WNF.0000000000000477 80. Gasparyan A, Navarroa D, Navarretea F, Manzanares J. Pharmacological strategies for post-traumatic stress disorder (PTSD): From animal to clinical studies. Neuropharmacology. 2022;218:n109211. DOI: 10.1016/j.neuropharm.2022.109211 81. Davidson JR, Brady K, Mellman TA, et al. The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. J Clin Psychopharmacol. 2007;27(1):85–8. DOI: 10.1097/JCP.0b013e31802e5115 82. Kinrys G, Wygant L, Pardo TB, et al. Levetiracetam for treatment-refractory posttraumatic stress disorder. J Clin Psychiatr. 2006;67(2):211–4. DOI: 10.4088/jcp.v67n0206 83. Baniasadi M, Hosseini G, Fayyazi B, et al. Effect of pregabalin augmentation in treatment of patients with combat-related chronic posttraumatic stress disorder: a randomized controlled trial. J Psychiatr Pract. 2014;20(6):419–27. DOI: 10.1097/01.pra.0000456590.12998.41 84. De Crescenzo F, D'Alò GL, Ostinelli EG, et al. Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. Lancet. 2022;400(10347):170–84. DOI: 10.1016/S0140-6736(22)00878-9 85. Lappas AS, Glarou E, Polyzopoulou ZA, et al. Pharmacotherapy for sleep disturbances in post-traumatic stress disorder (PTSD): A network meta-analysis. Sleep Med. 2024;119:467–79. DOI: 10.1016/j.sleep.2024.05.032 86. Guina J, Rossetter SR, DeRhodes BJ, et al. Benzodiazepines for PTSD: A Systematic Review and Meta-Analysis. J Psychiatr Pract. 2015;21(4):281–303. DOI: 10.1097/PRA.0000000000000091 87. Huang CY, Zhao YF, Zhang ZX, et al. Psychotherapeutic and pharmacological agents for post-traumatic stress disorder with sleep disorder: network meta-analysis. Ann Med. 2024;56(1):2381696. DOI: 10.1080/07853890.2024.2381696 88. Duffy JD, Malloy PF. Efficacy of buspirone in the treatment of posttraumatic stress disorder: an open trial. Ann Clin Psychiatry. 1994;6(1):33–7. DOI: 10.3109/10401239409148837 89. Hamner M, Ulmer H, Horne D. Buspirone potentiation of antidepressants in the treatment of PTSD. Depress Anxiety. 1997;5(3):137–9. DOI: 10.1002/(SICI)1520-6394(1997)5:3<137::AID-DA6>3.0.CO;2-B 90. Vasileva AV. [Post-traumatic stress disorder – from traumatic neurosis to ICD-11: features of diagnosis and selection of therapy]. Meditsinskiy sovet [Medical Council]. 2023;(3):94–108. (In Russ.) DOI: 10.21518/ms2023-083 91. Malikowska-Racia N, Salat K. Recent advances in the neurobiology of posttraumatic stress disorder: A review of possible mechanisms underlying an effective pharmacotherapy. Pharmacol Res. 2019;142:30–49. DOI: 10.1016/j.phrs.2019.02.001 92. Stein DJ. Etifoxine versus alprazolam for the treatment of adjustment disorder with anxiety: a randomized controlled trial. Adv Ther. 2015;32(1):57–68. DOI: 10.1007/s12325-015-0176-6 93. Zhang Y, Ren R, Sanford LD, et al. The effects of prazosin on sleep disturbances in post-traumatic stress disorder: a systematic review and meta-analysis. Sleep Med. 2020;67:225–31. DOI: 10.1016/j.sleep.2019.06.010 94. Reist C, Streja E, Tang CC, et al. Prazosin for treatment of post-traumatic stress disorder: A systematic review and meta-analysis. CNS Spectr. 2021;26(4):338–44. DOI: 10.1017/S1092852920001121
Метрики статей
Metrics powered by PLOS ALM